Phathom Pharmaceuticals Inc (PHAT) Gross Profit Margin starting from the third quarter 2026 to third quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Phathom Pharmaceuticals Inc   (NASDAQ: PHAT)


Phathom Pharmaceuticals Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PHAT Gross Profit Margin (Sep 30 2026)
Q3 		(Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Revenue Change 71.14 %
Seq. Revenue Change 14.07 %
Revenue In Millions $84.72
Gross Profit Margin 78.32 %
Gross Profit Margin Total Ranking # 676
Gross Profit In Millions $66.35
Y / Y Gross Profit Change 53.2 %
Seq. Gross Profit Change 12.13 %


Commenting Third Quarter 2026 Gross Profit Margin
Phathom Pharmaceuticals Inc has managed to improve its Revenue sequentially to $84.72 millions by 14.07 % faster than Gross Profit increase of 12.13 % to $66.35 millions, this led to contraction in Gross Profit Margin to 78.32 %, below company average.


Observing third quarter 2026 results within Major Pharmaceutical Preparations industry 67 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from 493 to 676.
Learn about Gross Margin
PHAT's Gross Profit Margin third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 68
Healthcare Sector # 119
Overall # 670

Gross Profit Margin Statistics
High Average Low
87.5 % 82.75 % 75.51 %
(Sep 30 2025)   (Dec 31 2023)


PHAT Gross Income Trends • More of PHAT's Profitabilty Ratios • PHAT Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
PHAT's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
PHAT's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for PHAT's Competitors
Gross Profit Margin Profit Margin for Phathom Pharmaceuticals Inc 's Suppliers
Gross Profit Margin Profit Margin for PHAT's Customers

You may also want to know
PHAT's Annual Growth Rates PHAT's Profitability Ratios PHAT's Asset Turnover Ratio PHAT's Dividend Growth
PHAT's Roe PHAT's Valuation Ratios PHAT's Financial Strength Ratios PHAT's Gross Profit Growth
PHAT's Roa PHAT's Inventory Turnover Ratio PHAT's Growth Rates PHAT's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Gross Profit MarginSep 30 2026 MRQ Gross ProfitSep 30 2026 MRQ Revenue
Protagonist Therapeutics inc   99.60 %$ 273.310  Millions$ 274.410  Millions
Lexicon Pharmaceuticals Inc   99.30 %$ 11.171  Millions$ 11.250  Millions
Verastem Inc   98.84 %$ 23.733  Millions$ 24.012  Millions
Travere Therapeutics Inc   98.72 %$ 221.696  Millions$ 224.563  Millions
Adc Therapeutics Sa  98.67 %$ 21.428  Millions$ 21.716  Millions
Corcept Therapeutics Inc  98.65 %$ 335.864  Millions$ 340.472  Millions
Ionis Pharmaceuticals Inc   98.63 %$ 239.399  Millions$ 242.721  Millions
Verrica Pharmaceuticals Inc   98.55 %$ 6.814  Millions$ 6.914  Millions
Kura Oncology Inc   98.38 %$ 22.468  Millions$ 22.839  Millions
Ardelyx inc   96.44 %$ 123.116  Millions$ 127.655  Millions
Uniqure N v   95.46 %$ 4.960  Millions$ 5.196  Millions
Agios Pharmaceuticals Inc   95.44 %$ 52.860  Millions$ 55.385  Millions
Zevra Therapeutics Inc   95.25 %$ 35.962  Millions$ 37.756  Millions
Bridgebio Pharma Inc   94.21 %$ 332.721  Millions$ 353.171  Millions
Biofrontera Inc   94.11 %$ 8.536  Millions$ 9.070  Millions
Gyre Therapeutics Inc   94.09 %$ 30.987  Millions$ 32.934  Millions
Vanda Pharmaceuticals Inc   94.05 %$ 65.663  Millions$ 69.815  Millions
Axsome Therapeutics Inc   93.14 %$ 241.887  Millions$ 259.691  Millions
Tonix Pharmaceuticals Holding Corp   92.74 %$ 15.982  Millions$ 17.234  Millions
Urogen Pharma Ltd   91.57 %$ 81.499  Millions$ 89.001  Millions
Arcutis Biotherapeutics Inc   91.34 %$ 131.459  Millions$ 143.919  Millions
Roivant Sciences Ltd   90.47 %$ 31.774  Millions$ 35.121  Millions
Kiniksa Pharmaceuticals International Plc  90.29 %$ 258.211  Millions$ 285.970  Millions
Aurinia Pharmaceuticals Inc   90.08 %$ 75.393  Millions$ 83.699  Millions
Acadia Pharmaceuticals Inc   89.75 %$ 307.201  Millions$ 342.291  Millions
Mannkind Corporation  88.99 %$ 90.657  Millions$ 101.870  Millions
Regeneron Pharmaceuticals Inc   88.79 %$ 4,542.200  Millions$ 5,115.800  Millions
Ocular Therapeutix Inc   88.70 %$ 11.419  Millions$ 12.874  Millions
Beone Medicines Ltd   88.52 %$ 1,672.919  Millions$ 1,889.815  Millions
Xeris Biopharma Holdings Inc   88.41 %$ 94.796  Millions$ 107.225  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.